Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 61,160	$ 56,334	$ 54,318
Cost of products sold	18,204	16,904	20,415
Selling, general and administrative	14,010	14,752	12,872
Research and development	9,096	12,791	7,675
Acquired IPR&D and milestones	5,016	2,757	778
Other operating income	(241)	(7)	(179)
Total operating costs and expenses	46,085	47,197	41,561
Operating earnings	15,075	9,137	12,757
Interest expense, net	2,627	2,160	1,684
Net foreign exchange loss	58	21	146
Other expense, net	5,793	3,240	4,677
Earnings before income tax expense	6,597	3,716	6,250
Income tax expense (benefit)	2,364	(570)	1,377
Net earnings	4,233	4,286	4,873
Net earnings attributable to noncontrolling interest	7	8	10
Net earnings attributable to AbbVie Inc.	$ 4,226	$ 4,278	$ 4,863
Per share data
Basic earnings per share (in dollars per share)	$ 2.37	$ 2.40	$ 2.73
Diluted earnings per share (in dollars per share)	$ 2.36	$ 2.39	$ 2.72
Weighted-average basic shares outstanding (in shares)	1,769	1,769	1,768
Weighted-average diluted shares outstanding (in shares)	1,773	1,773	1,773

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net earnings	$ 4,233	$ 4,286	$ 4,873
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	762	764	752
Amortization of intangible assets	7,377	7,622	7,946
Deferred income taxes	(492)	(1,449)	(2,889)
Change in fair value of contingent consideration liabilities	6,495	3,771	5,128
Payments of contingent consideration liabilities	(2,865)	(1,995)	(870)
Stock-based compensation	955	911	747
Acquired IPR&D and milestones	5,016	2,757	778
Non-cash litigation reserve adjustments, net of cash payments	(933)	508	(443)
Impairment of intangible assets	847	4,476	4,229
Other, net	(3)	(63)	(225)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,490)	207	66
Inventories	(234)	(319)	(417)
Prepaid expenses and other assets	(827)	361	(188)
Accounts payable and other liabilities	951	177	3,840
Income tax assets and liabilities, net	(762)	(3,208)	(488)
Cash flows from operating activities	19,030	18,806	22,839
Cash flows from investing activities
Acquisition of businesses, net of cash acquired	(204)	(17,493)	0
Other acquisitions and investments, net of cash acquired	(5,237)	(3,024)	(1,223)
Acquisitions of property and equipment	(1,214)	(974)	(777)
Purchases of investment securities	(35)	(73)	(77)
Sales and maturities of investment securities	76	555	55
Other, net	(29)	189	13
Cash flows from investing activities	(6,643)	(20,820)	(2,009)
Cash flows from financing activities
Net change in commercial paper borrowings with original maturities of three months or less	499	0	0
Proceeds from Short-Term Debt	4,798	5,008	0
Repayments of Other Short-Term Debt	(2,798)	(5,008)	0
Proceeds from issuance of long-term debt	3,994	16,963
Repayments of long-term debt and finance lease obligations	(6,797)	(9,613)	(4,149)
Debt issuance costs	(23)	(99)	(38)
Dividends paid	(11,657)	(11,025)	(10,539)
Purchases of treasury stock	(980)	(1,708)	(1,972)
Proceeds from the exercise of stock options	172	214	180
Payments of contingent consideration liabilities	0	0	(752)
Other, net	68	57	48
Cash flows from financing activities	(12,724)	(5,211)	(17,222)
Effect of exchange rate changes on cash and equivalents	42	(65)	5
Net change in cash and equivalents	(295)	(7,290)	3,613
Cash and equivalents, beginning of year	5,524	12,814	9,201
Cash and equivalents, end of year	5,229	5,524	12,814
Other supplemental information
Interest paid, net of portion capitalized	$ 3,002	$ 2,811	$ 2,469

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current assets
Cash and equivalents	$ 5,229	$ 5,524
Short-term investments	28	31
Accounts receivable, net	12,589	10,919
Inventories	4,951	4,181
Prepaid expenses and other	6,265	4,927
Total current assets	29,062	25,582
Investments	268	279
Property and equipment, net	5,628	5,134
Intangible assets, net	52,641	60,068
Goodwill	35,640	34,956
Other assets	10,721	9,142
Total assets	133,960	135,161
Current liabilities
Short-term borrowings	2,499	0
Current portion of long-term debt and finance lease obligations	6,056	6,804
Accounts payable and accrued liabilities	34,734	31,945
Total current liabilities	43,289	38,749
Long-term debt and finance lease obligations	58,941	60,340
Deferred income taxes	2,389	2,579
Other long-term liabilities	32,569	30,129
Commitments and contingencies
Stockholders' equity (deficit)
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,678,628 shares issued as of December 31, 2025 and 1,831,594,494 as of December 31, 2024	18	18
Common stock held in treasury, at cost, 70,802,593 shares as of December 31, 2025 and 66,337,508 as of December 31, 2024	(9,146)	(8,201)
Additional paid-in capital	22,495	21,333
Accumulated deficit	(15,493)	(7,900)
Accumulated other comprehensive loss	(1,144)	(1,925)
Total stockholders' equity (deficit)	(3,270)	3,325
Noncontrolling interest	42	39
Total equity (deficit)	(3,228)	3,364
Total liabilities and equity	$ 133,960	$ 135,161